

APCCC Detailed Programme 2019 (subject to minor changes)

Areas of controversy

1. Locally advanced prostate cancer
2. Biochemical recurrence of prostate cancer after local therapy
3. Management of primary tumour in the metastatic situation
4. Newly diagnosed metastatic prostate cancer, including oligometastatic prostate cancer
5. Management of nmCRPC
6. Management of mCRPC
7. Bone and bone metastases
8. Molecular characterization: Tissue and blood
9. Heterogeneity of men with prostate cancer (ethnicity, elderly)
10. Side effects of hormonal treatments and their management

Thursday 29th August 2019

Time	Session		
09:00	Welcome Address Silke Gillessen and Aurelius Omlin on behalf of APCCC		
9:15 - 10:45 Session 1	Molecular biomarkers and novel imaging in APC	Chairs: Bristow, Padhani, Gleave	Duration
State of the art on molecular characterization in APC - Non-metastatic prostate cancer - Metastatic castration-naïve - Metastatic CRPC		Pritchard	15 minutes
Clinical utility of molecular markers		De Bono	15 minutes
Which men need genetic counselling and/or testing?		Eeles	15 minutes
Discussion			10 minutes
Advantages and pitfalls of PSMA PET/CT in APC imaging • Advantages • Pitfalls		Fanti Davis	10 minutes 10 minutes
Discussion (10min)			10 minutes
COFFEE BREAK			
11:15 – 12:45 Session 2	Node-positive prostate cancer (N1 but M0)	Chairs: Feng, Briganti, Higano	Duration
How to treat men with newly diagnosed cN1 cM0 a) based on classical imaging b) based on novel (next-generation) imaging			
• Surgery options		Murphy	12 minutes
• Radiation therapy options		Roach	12 minutes
• Systemic therapy options		James	12 minutes
Synthesis – How best to treat cN1 prostate cancer		Fizazi	10 minutes
Discussion			15 minutes
How to treat men with pathological node positive (pN1, cM0) prostate cancer?		Bossi	12 minutes
Discussion			10 minutes
12:45 – 13:45 LUNCH			

13:45 – 15:15 Session 3			
13:45 – 15:15 Session 3	PSA recurrence after radical local therapy and oligometastatic prostate cancer	Chairs: Khauli, Murthy, Zapatero	Duration
	Management of men with PSA recurrence after radical local radiation therapy	Feng	12 minutes
	Management of men with PSA recurrence or persistence after prostatectomy	Evans	12 minutes
Discussion			10 minutes
	Oligometastatic prostate cancer – Definitions and concepts	Reiter	10 minutes
	Treatment of <u>de novo</u> (newly diagnosed) oligometastatic prostate cancer	Morris	10 minutes
	Treatment of <u>oligorecurrent</u> prostate cancer after local therapy	Ost	10 minutes
	Please cover: Which patients should receive local, systemic, and/or metastasis-directed therapy?		
	Treatment of oligometastatic and oligoprogressive CRPC	Small	10 minutes
	Please cover: Progression after treatment for nmCRPC, progression on ADT + AR pathway inhibitors, and patients with metastatic disease who have only a few progressing lesions (oligoprogression)		
Discussion			16 minutes
COFFEE BREAK			
15:45 – 17:15 Session 4	Regional care (demographic and environmental factors)	Chairs: Halabi, Kanesvaran, Suzuki	Duration
	Ethnicity and prognosis	Logothetis	15 minutes
	Pharmaco-ethnicity and impact on treatment	Poon	15 minutes
	Report and lessons learned from the consensus conference for developing countries	Maluf	15 minutes
	Disparities in prostate cancer management in the U.S.	Morgans	15 minutes
	The ageing population: Oncogeriatric assessment and treatment considerations	O'Sullivan	15 minutes
Discussion			15 minutes

Friday 30 th August 2019			
Extra session 08:00 – 08:30	Movember Session	Duration	
	Outcomes Research – Ironman project	Kantoff	20 minutes
Discussion			10 minutes
08:30 – 10:15 Session 5	Management of metastatic castration-sensitive/naive prostate cancer	Chairs: Attard, Mottet; Heidenreich	Duration

Testosterone measurement – Which test and when?		Gleave	10 minutes
Local treatment of the primary (RT) in the metastatic situation		Bristow	10 minutes
Local treatment of the primary tumour (surgery) in the metastatic situation		Steuber	10 minutes
Discussion			10 minutes
Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer?		Sweeney	15 minutes
Addition of AR pathway inhibitors vs. docetaxel: Statisticians' perspective		Sydes	10 minutes
Synthesis – Optimal treatment of men with newly diagnosed prostate cancer		Clarke	10 minutes
Follow-up on ADT alone vs. ADT “plus”		Beer	10 minutes
Discussion			15 minutes
COFFEE BREAK			
10:45 – 12:45 Session 6	Management of castration-resistant prostate cancer (CRPC)	Chairs: Sternberg, Duran	Duration
Definition and overview of treatment options in nmCRPC		Scher	10 minutes
Debate: Treatment of nmCRPC			
• Pros		Hussain	8 minutes
• Cons		Higano	8 minutes
First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor		Taplin	12 minutes
Subgroup analysis of mCRPC clinical trials		Halabi	10 minutes
Discussion			12 minutes
PSMA targeted therapies		Hofman	12 minutes
Immunotherapy		Drake	12 minutes
PARP inhibition		Chi	12 minutes
Neuroendocrine spectrum: Diagnosis and treatment		Efstathiou	12 minutes
Discussion			12 minutes
12:45 – 13:45 LUNCH			
13:45 – 14:45 Session 7	Side effects of treatment and their management	Chairs: Bjartell, Leibowitz	Duration
Management of sexuality and incontinence issues in APC		Van Oort	10 minutes
Management of hot flushes		Frydenberg	10 minutes
Management of metabolic changes		Shore	10 minutes
Management of fatigue, cognition/dementia		Ryan	10 minutes

Optimal steroid use with abiraterone		Attard	10 minutes
Discussion			10 minutes
COFFEE BREAK			
15:15 – 16:45 Session 8	Bone and bone metastases	Chairs: Heinrich, Türkeri	Duration
Prevention/Treatment of osteoporosis		Saad	15 minutes
Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC			
• Only for very select men with CRPC and bone metastases		Parker	10 minutes
• For the majority of men with CRPC and bone metastases		Tombal	10 minutes
• Synthesis – Best use of antiresorptive therapy in CRPC		Smith	8 minutes
Discussion			5 minutes
Radium-223 and bone health agents		Sartor	15 minutes
The flare phenomenon in bone-metastatic APC		Padhani	10 minutes
Discussion			5 minutes
COFFEE BREAK			
17:15 – 18:15 Session 9	The future of APC management	Chair: Sade, Mrabti, Soule	Duration
Wishes from a patient's perspective		Millman	8 minutes
In locally advanced prostate cancer		Briganti	8 minutes
In oligometastatic prostate cancer		Beltran	8 minutes
In polymetastatic prostate cancer		Oh	8 minutes
In imaging		Fanti	8 minutes
In biomarkers		Rubin	8 minutes
Global access to treatments		Fizazi	8 minutes
Discussion			5 minutes

Saturday 31st of August 2019		
Time	Special Session	Speakers
	All participants will be able to attend the panel meeting as part of the conference.	
08:30 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS Moderation: Small and Tombal
COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS Moderation: Small and Tombal
Closing Remarks: S.Gillessen and A.Omlin		